...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.
【24h】

Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.

机译：大肠菌素单药治疗与大肠菌素-美罗培南联合治疗对多重耐药性革兰氏阴性细菌感染的有效性和肾毒性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A retrospective cohort study evaluated the effectiveness and nephrotoxicity of intravenous colistin monotherapy vs. colistin-meropenem combination therapy for patients with multidrug-resistant Gram-negative bacterial infections. Fourteen patients received intravenous colistin monotherapy and 57 received colistin-meropenem. No significant differences were found concerning clinical response of the infection (12/14 (85.7%) vs. 39/57 (68.4%), p 0.32) and development of nephrotoxicity (0/14 (0%) vs. 4/57 (7%), p 0.58). A favourable association was revealed between survival and treatment with colistin monotherapy compared to colistin-meropenem (0/14 (0%) vs. 21/57 (36.8%) deaths, p 0.007), even after adjusting for the variables for which significant differences were found.
机译：一项回顾性队列研究评估了对多药耐药的革兰氏阴性细菌感染患者的静脉粘菌素单药治疗与粘菌素-美罗培南联合治疗的有效性和肾毒性。 14名患者接受静脉粘菌素单药治疗，57例接受粘菌素美罗培南。在感染的临床反应（12/14（85.7％）vs. 39/57（68.4％），p 0.32）和肾毒性的发生（0/14（0％）vs. 4/57（ 7％），P = 0.58）。与大肠粘菌素-美罗培南相比，大肠粘菌素单药治疗的存活率与治疗之间存在良好的相关性（0/14（0％）vs. 21/57（36.8％）的死亡，P = 0.007），即使在对变量进行显着性调整之后被找到。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号